dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Fernández-Juárez, Gema |
dc.contributor.author | Rojas-Rivera, Jorge |
dc.contributor.author | van de Logt, Anne-Els |
dc.contributor.author | Justino, Joana |
dc.contributor.author | Sevillano, Angel |
dc.contributor.author | Agraz Pamplona, Irene |
dc.contributor.author | Caravaca-Fontán, Fernando |
dc.date.accessioned | 2022-01-28T07:09:28Z |
dc.date.available | 2022-01-28T07:09:28Z |
dc.date.copyright | 2020 |
dc.date.issued | 2021-04 |
dc.identifier.citation | Fernández-Juárez G, Rojas-Rivera J, Logt AV, Justino J, Sevillano A, Caravaca-Fontán F, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021 Apr;99(4):986–98. |
dc.identifier.issn | 1523-1755 |
dc.identifier.uri | https://hdl.handle.net/11351/6922 |
dc.description | Corticoides; Ciclofosfamida; Nefropatia membranosa primària |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Kidney International;99(4) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Ronyons - Malalties - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Kidney Diseases |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Treatment Outcome |
dc.title | The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.kint.2020.10.014 |
dc.subject.decs | enfermedades renales |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1016/j.kint.2020.10.014 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Fernández-Juárez G] Nephrology Division, Hospital Universitario Fundación Alcorcón, Madrid, Spain. [Rojas-Rivera J] Nephrology Division, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. [Logt AV] Nephrology Division, Radboud University Medical Center, Nijmegen, The Netherlands. [Justino J] Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), Université Côte d’Azur, Centre National de la Recherche Scientifique (CNRS), Valbonne Sophia Antipolis, France. [Sevillano A, Caravaca-Fontán F] Nephrology Division, Instituto de Investigación Hospital Universitario 12 Octubre, Madrid, Spain. [Agraz I] Divisió de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 33166580 |
dc.identifier.wos | 000740817900004 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |